TILS.L

Tiziana Life Sciences Plc
Tiziana Life Science - Director/PDMR Dealing
5th October 2021, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9853N
Tiziana Life Sciences PLC
05 October 2021
 

PDMR Dealing

London, New York, 5 October 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 60,000 ordinary shares of 3p each in the market at a price of 50p per share.

The acquisition takes Mr Cerrone's interests from 34.148% to 34.178% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code).

1.

Details of PDMR / person closely associated

a)

Name

Gabriele Cerrone

2.

Reason for the notification

a)

Position / status

Chairman

b)

Initial notification /amendment

Initial notification

3.

Details of the issuer

a)

Name

Tiziana Life Sciences plc

b)

LEI

213800CED47HI8PIOB36

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type  of transaction; (iii) each date; and (iv) each place where transactions have  been conducted

a)

Description of the financial instrument

Ordinary Shares of 3p each

b)

Identification code of the Financial Instrument

ISIN for Tiziana Life Sciences plc: GB00BKWNZY55

c)

Nature of the transaction

Market Purchase

d)

Price(s) and volume(s)

50p

60,000

f)

Date of the transaction

4 October 2021

g)

Place of the transaction

XLON  

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ:TLSA, UK LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to Milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody ("mAb") in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease ("IBD"), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor ("IL6R") mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

 

For further enquiries:

 

For further enquiries:

Tiziana Life Sciences plc

+44 (0)20 7495 2379  

Gabriele Cerrone, Chairman, and founder



   

United States:  

Investors:  

Dave Gentry, CEO  

RedChip Companies Inc.  

407-491-4498  

dave@redchip.com  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUSRORAOURRUA ]]>
TwitterFacebookLinkedIn